Invokana Lawsuit and FDA Side Effect Bone Fracture Warnings Call For A Closer Look At SGLT2 Inhibitor Drugs

February 25, 2016 – – TheProductLawyers.com reports on recent warnings from the U.S. Food and Drug Administration which discuss type-2 diabetes drugs Invokana and Invokamet, and note that, after what has been seen from adverse event reports, it appears that the drugs may decrease the bone density of patients taking it, therefore increasing their risk of bone fractures. Warning labels on each of these drugs have indicated a potential bone fracture risk from the start, however, the FDA has required a change to these warnings recently, which will note that bone fractures are likely more common among patients taking Invokana when compared with those taking placebo pills.

FDA statements read, “Fractures were observed as early as 12 weeks after treatment initiation, and were more likely to be low trauma (e.g., arising after falls from no more than standing height) and affect the upper extremities.” The comment seems to indicate that fractures have been found to occur easily for patients using the drug. In addition, the FDA discussed something else that had been noted in studies: a marked overall decrease in bone mineral density for patients using the drugs. The organization discussed a study which evaluated 714 elderly patients. Those who used Invokana showed increased bone loss in both their hip and spine areas.

Invokana’s potential link to bone loss, (as well as bone loss links to other SGLT2-inhibitor class drugs) has been something that has reportedly been watched and monitored by the FDA for a number of years now. The Endocrinologic and Metabolic Drugs Advisory Committee also issued a public safety warning discussing bone fractures which were reportedly observed after clinical trials on the drug in 2013; the year that it was approved and sent to market.

The attorneys at Banville Law sponsor additional online resources regarding Invokana on TheProductLawyers.com, and understand the seriousness of the many health conditions which have recently been linked to SGLT2 inhibitor class drugs, including Invokana. At this time, they are working to help ensure that patients who have used these types of diabetes drugs and who have also suffered from health problems will have the opportunity to investigate their legal rights in full. Currently, the attorneys of Banville Law are offering free legal consultations to those who are interested in pursuing justice, as they may be entitled to legal action and significant compensation.

To request further Invokana information, or to ask questions, contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008358